Sandip K. Sen Gupta
Sandip K. Sen Gupta, MD, FRCPC, FCAP, CCPE
Professor of Pathology and Molecular Medicine

Queen’s University


1983 Doctorate in Medicine(University of Ottawa)
1983 – 1988 General Pathology Residency Program(Queen’s University)
1984 Diplomat, National Board of Medical Examiners, U.S.A.       
1987 Licentiate, Medical Council of Canada
1987 General Medical License (College of Physicians & Surgeons of Ontario)
1988 Certification in General Pathology (Royal College of Physicians & Surgeons)
1988 Fellow, Division of Medicine (Royal College of Physicians and Surgeons)    
1989 Diplomate in Anatomic and Clinical Pathology (American Board of Pathology)
1989 Fellow, College of American Pathologists
1995 - 2000 Physician Manager Institute Series Certificates (Levels I – IV)
2011 Canadian Certified Physician Executive (Canadian Medical Association)



Dr. Sandip SenGupta completed his undergraduate medical education at the University of Ottawa (1983) and his postgraduate medical education (in General Pathology) at Queen’s  and has been a full time faculty member in the Faculty in Health Sciences since 1988. He holds a cross-appointment in the Department of Oncology (since 2012). 
Dr. SenGupta has a unique background of professional experienceas both a generalist and a subspecialist in Laboratory Medicine and Pathology/Oncology. In addition to his primary clinical and academic roles at Queen’s, he has served intramurally and extramurally in appointed and elected offices,  including as President of the KGH-HDH Medical Staff Association, President of the Ontario Association of Pathologists, and President of the Canadian Association of Pathologists.  Currently he is the Chair of the Breast National Cancer Pathology and Staging Multidisciplinary Expert Panel at the Canadian Partnership Against Cancer.

Research Interest

  • surgical pathology of breast diseases, focused on diagnostic oncology, including breast cancer biomarker validation, interpretation, and quality assurance
  • surgical pathology of musculoskeletal disorders and soft tissue tumours
  • regional laboratory outreach program development
  • quality improvement, quality design, patient safety, and utilization management in laboratory medicine 
  • The identification and validation of prognostic and predictive tissue-based biomarkers for the optimal management of breast cancer patients.
  • Multi-institutional breast cancer studies:  molecular epidemiology, DCIS, HER-2/neu

Professional Activities:

1988-1998 Assistant Professor Department of Pathology Queen’s University
1998-2005 Associate Professor Department of Pathology Queen’s University
2005 - present Professor Department of Pathology and Molecular Medicine Queen’s University
2012 - present Professor Department of Oncology Queen’s University


1988 - present Regular Attending Medical Staff Kingston General Hospital
1988 - present Regular Attending Medical Staff Hotel Dieu Hospital
1988-1999 Attending Medical Staff Prince Edward County Memorial Hospital
1989 - present Consulting Medical Staff Lennox & Addington County General Hospital
1991-1995 Consulting Medical Staff Smiths Falls Community Hospital
1995 - present Consultant Medical Staff Perth & Smiths Falls District Hospital
1997 – 2014 Active Medical Staff Ongwanada, Kingston
2012 - present Attending Medical Staff Providence Care Centre, Kingston



  1. Jackson AC, SenGupta SK, Smith JF.  Pathogenesis of Venezuelan Equine Encephalitis Virus Infection in Mice and Hamsters.  Vet Pathol: 28:410-418, 1991.
  2. SenGupta SK, Nag S.  Cervical Paravertebral Leiomyosarcoma Mimicking a Nerve Sheath Tumour. Human Pathology, July 1992.
  3. Chan W, SenGupta SK.  PostirradiationAngiosarcoma of the Vaginal Vault. Arch Pathol Lab Med;115:527-528, 1991.
  4. Sterns EE, Zee B, SenGupta SK, Saunders FW.  Thermography: Its Relation to Pathologic Characteristics, Vascularity, Proliferation Rate and Survival in Invasive Ductal Carcinoma of the Breast.  Cancer; 77:1324-8, 1996.
  5. Bhardwaj B, Klassen J, Cossette N, Sterns E, Tuck A, Deeley R, SenGupta SK, Elliott B.  Localization of Platelet-Derived Growth Factor Beta Receptor Expression in the Peri-Epithelial Stroma of Human Breast Carcinoma.  Clinical Cancer Research; Vol. 2, 773-782, 1996.
  6. Sterns EE, SenGupta SK, Saunders FW, Zee B.  Vascularity demonstrated by doppler ultrasound and immunohistochemistry in invasive ductal carcinoma of the breast.  Breast Cancer Research and Treatment; 40:197-203, 1996.
  7. Sterns EE, SenGupta SK, Zee B.  Macromolecular interstitial clearance, tumour vascularity, other prognostic factors and breast cancer survival.  Breast Cancer Research and Treatment; 42:113-120, 1997.
  8. SenGupta SK, More D, Manley PN.  Integrating Academic and Community Laboratory Needs: Developing a Successful Outreach Program.  Clinical Laboratory Management Review. 11(1):33-8.
  9. Aronson KJ, Miller AB, Woolcott CG, Sterns EE, McCready DR, Lickley LA, Fish EB, Hiraki GY, Holloway C, Ross T, Hanna WM, SenGupta SK, Weber JP.  Breast adipose tissue concentrations of polychlorinated biphenyls and other organochlorines and breast cancer risk.  Cancer Epidemiology, Biomarkers and Prevention; 01; 9(1):55-63, 2000. 
  10. Ginsburg AD, SenGupta SK, Clarke G.  Applicability of Proposed Prognostic Categories to a Population of Systemically Untreated Patients with Node-Negative Breast Cancer.  Current Oncology; Vol. 6, No. 4: 246-250, 1999.
  11. More D, SenGupta SK, Manley PN.  Promoting, Building and Sustaining a Regional Laboratory Network in a Changing Environment.  Clinical Leadership Management Review; 14(5):205-10.
  12. Woolcott CG, Aronson KJ, Hanna WM, SenGupta SK, McCready DR, Sterns EE, Miller AB.  Organochlorines and breast cancer risk by receptor status, tumour size and grade.  Cancer Causes and Control; 12(5):395-404, 2001.
  13. Isotalo PA, George R, SenGupta SK.Malignant Phyllodes Tumour with Liposarcomatous Differentiation.  Arch Pathol Lab Med; 04; 129(3):421-2, 2005.
  14. Elliott BE, Meens JA, SenGupta SK, Louvard D, Arpin M.  The membrane cytoskeleton crosslinkerezrin is required for metastasis of breast carcinoma cells.  Breast Cancer Res; 02; 7(3):R365-73, 2005.
  15. Hanna W, O’Malley FP, Barnes P, Berendt R, Gaboury L, Magliocco A, Pettigrew N, Robertson S, SenGupta SK, Tetu B, Thomson T.  Updated recommendations from the Canadian National Consensus Meeting on HER2/neu testing in breast cancer.  Current Oncology; August 2007.
  16. Woolcott CG, SenGupta SK, Hanna WM, Aronson K.  Estrogen and progesterone receptor levels in nonneoplastic breast epithelium of breast cancer cases versus benign breast biopsy controls.  BMC Cancer; 02; 8:130, 2008.
  17.  Jefferson T, Torlakovic E, Garratt J, Miller D, Kobel M, Cooper J, Bahzad S, Pilavdzic D, O’Malley F, O’Brien A, SenGupta SK, Alport E, Tetu B, Knight B, Pettigrew N, Berendt R, Wolber R, Trotter M, Riddell R, Gaboury L, Elms F, Magliocco A, Barnes P, Gown A, Gilks.  Implementation of a Canadian External Quality Assurance Program for Breast Cancer Biomarkers: an initiative of Canadian Quality Control in Immunohistochemistry (cIQc) and Canadian Association of Pathologists (CAP) National Standards Committee Immunohistochemistry. Applied Immunohistochemistry & molecular morphology; 04; 17 (5):375-82, 2009.
  18. Chen C.-H., Rowlands C, SenGupta SK, O’Malley F, George RL, Isotalo PA.  Primary Basaloid Carcinoma of the Nipple with Associated Squamous Cell Carcinoma in Situ: A Case Report and Literature Review. The Breast Journal; 01; 15(4):409-13, 2009.
  19.  Beiko D, Roldan H, SenGupta SK, George R.  Laparoscopic excision of a large extra-adrenal perirenalmyelolipoma.  Canadian Urological Association Journal; 04; 4(2):E39-41, 2010.
  20. Church A, Jones S, Silva M, SenGupta SK.KaposiformHemangioendothelioma and Kasabach-Merritt syndrome: A Case Report with Clinical Followup.  Canadian Journal of Pathology; Vol. 2, Issue 2, Summer 2010.
  21. Rajput AB, Hu N, Varma S, Chen C-H, Ding K, Park PC, Chapman J-A W, SenGupta SK, Madarnas Y, Elliott BE, Feilotter HE. Immunohistochemical Assessment of Expression of Centromer Protein-A (CENPA) in Human Invasive Breast Cancer.  Cancers; 01; 3(4):4212-27,2011.
  22. Mak H, Naba A, Varma S, Schick C, Day A, SenGupta SK, Arpin M, Elliott BE.  Ezrin phosphorylation on tyrosine 477 regulates invasion and metastasis of breast cancer cells.  BMC Cancer; 03; 12/82 (IF:3.01), 2012.
  23. Cass JD, Varma S, Day AG, Sangrar W, Rajput AB, Raptis LH, Squire J, Madarnas Y, SenGupta SK, Elliott BE.  Automated Quantitative Analysis of p53, Cyclin D1, Ki67 and pERK Expression in Breast Carcinoma Does Not Differ from Expert Pathologist Scoring and Correlates with Clinico-Pathological Characteristics.  Cancers; 01; 4(3):725-42. (IF: open access), 2012.
  24. Skelhorne-Gross G, Reid AL, Apostoli AJ, Di Lena MA, Rubino RE, Peterson NT, Schneider M, SenGupta SK, Gonzales FJ, Nicol CJ.  Stromal adipocyte PPARgamma protects against breast tumorigenesis.  Carcinogenesis 05; 33(7): 1412-20.  PMID:22581835, 2012.
  25.  Hanna W, Barnes P, Berendt R, Chang M, Magliocco A, Mulligan AM, Rees H, Miller N, Elavathil L, Gilks B, Pettigrew N, Pilavdzic D, SenGupta SK.  HER2 testing in breast cancer: current pathology challenges faced in Canada.  Current Oncology; Volume 19, Number 6, pp. 315-323, 2012.
  26.  Rakovitch E, Nofech-Mozes S, Narod SA, Hanna W, Thiruchelvam D, Saskin R,  Taylor C, Tuck A, SenGupta SK, Elavathil L, Jani PA, Done SJ, Miller N, Youngson B, Kong I, Paszat P.  Can we select individuals with low risk ductal carcinoma in situ (DCIS)? A population-based outcomes analysis?Breast Cancer Research and Treatment 03/2013.
  27.  Rakovitch E, Narod S, Nofech-Moses S, Hanna W, Thiruchelvam T, Saskin R, Taylor C, Tuck A, Youngson B, Miller N, Done SD, SenGupta SK, Elavathil L, Jani PA, Bonin M, Metcalfe S, Paszat L.  Impact of Boost Radiation in the Treatment of Ductal Carcinoma In Situ: A Population-Based Analysis.International journal of radiation oncology, biology, physics; 07; 86(3):491-497, 2013.
  28. Grundy A, Richardson H, Burstyn I, Lohrisch C, SenGupta SK, Lai AS, Lee D, Spinelli JJ, Aronson KJ. Increased risk of breast cancer associated with long-term shift work in Canada.Occup Environ Meddoi:10.1136/oemed-101482, 2013.
  29. Apostoli AJ, Skelhorne-Gross GEA, Rubino RE, Peterson NT, Di LenaMA, Schneider MM, SenGupta SK, Nicol CJB.  Loss of PPARy expression in mammary secretory epithelial cells creates a pro-breast tumourigenic environment. International Journal of Cancer; 08
  30. Ghaffari A, Hoskin V, Szeto A, Hum M, Liaghati N, Nakatsu K, Madarnas Y, SenGupta SK, Elliott BE.  A novel role for ezrin in breast cancer angio/lymphangiogenesis.  Breast Cancer Res; 16(5): p. 438, 2014.
  31.  Hanna WM, Barnes PJ, Chang MC, Gilks B, Magliocco A, Rees H, Robertson SJ, SenGupta SK, Nofech-Mozes S.  HER2 Testing in Primary Breast Cancer in the Era of Standardized Testing: A Canadian Prospective Study. Journal of Clinical Oncology (JCO/2014/556092 – Epub November 10, 2014.
  32. Rakovitch E, Lalani N, Paszat L, Sutradhar R, Thiruchelvam D, Nofech-Mozes S, Hanna W, Slodkowska E, Done SJ, Miller N, Youngson B, Tuck A, SenGupta SK, Elavathil L, Chang MC, Jani PA, Bonin M.  Long-term Outcomes of Hypofractionation versus Conventional Radiotherapy Following Breast Conserving Surgery for Ductal Carcinoma in Situ of the Breast.  The ASCO Post; November 2014
  33. Brackstone M, Fletcher GG, Dayes IS, Madarnas Y, SenGupta SK, Verma S. Locoregional therapy of locally advanced breast cancer: a clinical practice guideline. CurrOncol. 2015; 22(Suppl 1):S54-66.
  34. Baldassare T, Watt K, Truesdell P, Meens J, Schneider MM, SenGupta SK, Craig AW.  Endophilin A2 Promotes Triple-Negative Breast Cancer Cell Invasion and Tumor Metastasis.  Molecular Cancer Research03/2015
  35. Apostoli AJ, Roche JM, Schneider MM, SenGupta SK, Di Lena MA, Rubino RE, Peterson NT, Nicol CJB.  Opposing Roles for Mammary Epithelial-Specific PPARgamma Signaling and Activation During Breast Tumour Progression.  Molecular Cancer 2015, 14:85 DOI: 10.1186/s12943-015-0347-8.
  36. Klein J, Kong I, Paszat L, Nofech-Mozes S, Hanna W, Thiruchelvam D, Saskin R, Done SJ, Miller N, Youngson B, Tuck A, SenGupta SK, Elavathil E, Jani PA, Slodkowska E, Rakovitch E.  Close or Positive Resection Margins are Not Associated With an Increased Risk of Chest Wall Recurrence in Women with DCIS Treated by Mastectomy: A Population-Based Analysis.SpringerPlus 2015, 4:335
  37. Rakovitch E, Nofech-Mozes S, Hanna W, Baehner FL, Saskin R, Butler SM, Tuck A, SenGupta SK, Elavathil L, Jani PA, Bonin M, Chang MC, Slodkowska E, Anderson JM, Jamshidian F, Cherbavaz DB.  A Population-Based Validation Study of the DCIS Score Predicting Recurrence Risk in Individuals Treated by Breast-Conserving Surgery Alone. Breast Cancer Research and Treatment 2015152:3464
  38. Shi J, Grundy A, Schultz J, Richardson H, Burstyn I, Lohrisch CA, SenGupta SK, Lai AS, Brooks-Wilson A, Spinelli JJ, Aronson KJ.  Genetic variation in vitamin D-related genes and risk of breast cancer among women of European and East Asian descent.Tumor Biology 2015
  39. Mukhopadhyay UK, Cass J, Raptis L, Craig AW, Bourdeau V, Varma S, SenGupta SK, Elliott BE.  STAT5A is regulated by DNA damage via the tumour suppressor p53.  Cytokine

On-Line Publications

  1. The Role of Trastuzumab (Herceptin) in the Treatment of Women with HER2/neu-Overexpressing Metastatic Breast Cancer (2005)
  2. The Role of Aromatase Inhibitors in Adjuvant Therapy for Postmenopausal Women with Hormone Receptor-Positive Breast Cancer (2005).
  3. The Role of Traztuzumab in Adjuvant and Neoadjuvant Therapy in Women with HER2/neu-Overexpressing Breast Cancer: A Clinical Practice Guideline (2006).
  4. Adjuvant Taxane Therapy for Women with Early-Stage, Invasive Breast Cancer (2006). 
  5. Management of Ductal Carcinoma in Situ of the Breast (2006).
  6. The Role of Gemcitabine in the Management of Metastatic Breast Cancer (2006).
  7. The Role of HER2/neu in Systemic and Radiation Therapy for Women with Breast Cancer (2006).
  8. Sentinel Lymph Node Biopsy in Early-Stage Breast Cancer: Recommendations (2008).
  9. Use of Bisphosphonates in Women with Breast Cancer (2012)
  10. Breast Pathology Second Review (2013).
  11. Locoregional Therapy of Locally Advanced Breast Cancer: Guideline Recommendations (2014).
  12. Breast Cancer Pathway Map (2015).
  13. Breast cancer reconstruction surgery (immediate and delayed) across Ontario: Patient indications and appropriate surgical options (2016).
  14. Optimal Treatment Strategies for Localized Ewing’s Sarcoma of Bone after Neo-adjuvant Chemotherapy (2016). 


clinical-laboratory-medicine-flyer Flyer